Cipla Share: Company’s Goa plant receives 6 objections from US FDA
Pharma company Cipla Limited has informed that the US Food and Drug Administration (USFDA) inspected the company manufacturing facility in Goa from June 10 to June 21, 2024. Following this inspection, Cipla has received 6 inspection observations recorded in Form 483. Cipla said in a regulatory filing, “USFDA has inspected the company’s manufacturing facility in Goa from 10 to 21 June 2024. After the inspection, six inspection related objections have been issued to the company in Form 483.
Cipla assured the stakeholders that it will work closely with the USFDA to address these observations within the stipulated time frame. The statement said. Form 483, an important part of the regulatory process, is a list of objections raised during the inspection and is issued by USFDA inspectors after the inspection is completed.
Stock performance
On Friday, the company’s shares closed at Rs 1,537.25 with a decline of 0.49 percent. The 52 week high of the share is Rs and in the last one year the company’s shares have seen an increase of 52.37 percent.